M. Stilwell

发表

Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, International journal of antimicrobial agents.

Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).

Ronald N. Jones, T. Fritsche, M. Stilwell, 2006, Diagnostic microbiology and infectious disease.

Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Symposium section Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae

Ronald N. Jones, T. Fritsche, H. Sader, 2007 .

Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011).

Ronald N. Jones, H. Sader, R. Flamm, 2014, International journal of antimicrobial agents.

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Ronald N. Jones, B. Goldstein, T. Fritsche, 2006, Diagnostic microbiology and infectious disease.

Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).

Ronald N. Jones, P. Rhomberg, H. Sader, 2009, Diagnostic microbiology and infectious disease.

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.

M. Pfaller, R. Jones, M. Stilwell, 2001, Diagnostic microbiology and infectious disease.

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains).

Ronald N. Jones, M. Stilwell, 2013, Diagnostic microbiology and infectious disease.

Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

Ronald N. Jones, Gary J. Moet, T. Fritsche, 2007, Diagnostic microbiology and infectious disease.

O365 10 years of surveillance of bloodstream infections in European medical centres by the SENTRY Antimicrobial Surveillance Program (1997–2006)

T. Fritsche, H. Sader, M. Stilwell, 2007 .

Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.

Ronald N. Jones, C. Arias, B. Murray, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program

Ronald N. Jones, D. Sheehan, P. Hogan, 2007, Antimicrobial Agents and Chemotherapy.

Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens.

Michael L Wilson, Ronald N. Jones, R. Mendes, 2013, Diagnostic microbiology and infectious disease.

Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.

Michael L Wilson, Ronald N. Jones, M. Weinstein, 2013, Diagnostic microbiology and infectious disease.

Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species.

Ronald N. Jones, H. Sader, R. Flamm, 2013, Diagnostic microbiology and infectious disease.

In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.

Ronald N. Jones, J. Turnidge, H. Sader, 2009, Diagnostic microbiology and infectious disease.